Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumours 1

Interventions

AZD 6244 5GSK 1363089 3molibresib 2pazopanib 1ispinesib 1enzalutamide 1brigimadlin 1abiraterone 1Topotecan 1SLC-0111 1Rifampin 1Prednisone 1Omeprazole 1Moxifloxacin 1Midazolam 1Itraconazole 1Granisetron 1Fluconazole 1Famotidine 1Doxorubicin 1Cytochrome P-450 CYP3A 1Cytochrome P-450 CYP2C19 1Cytochrome P-450 CYP1A2 1Carboplatin 1Carbon-14 1Caffeine 1CH5183284 1BGC945 12-((3-((4-((5-(2-((3-fluorophenyl)amino)-2-oxoethyl)-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumours × Cytochrome P-450 CYP1A2 × Other solid neoplasm × Clear all
NCT03333824 2019-03-25

Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer

AstraZeneca

Phase 1 Completed
33 enrolled
Other solid neoplasm

Solid Tumours

Data powered by HemOnc (CC BY 4.0) Colophon âš¡